IntelliPharmaCeutics, Elan Settle Focalin Patent Spat
IntelliPharmaCeutics Corp. has struck a settlement in Elan Pharma International Ltd.'s patent infringement suit over a generic version of attention deficit hyperactivity disorder drug Focalin XR....To view the full article, register now.
Already a subscriber? Click here to view full article